3ti8: Difference between revisions

← Older edit

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA

@@ Line 1: / Line 1: @@
-[[Image:3ti8.jpg|left|200px]]
-<!--
+==Crystal structure of influenza A virus neuraminidase N5 complexed with laninamivir==
-The line below this paragraph, containing "STRUCTURE_3ti8", creates the "Structure Box" on the page.
+<StructureSection load='3ti8' size='340' side='right'caption='[[3ti8]], [[Resolution|resolution]] 1.60&Aring;' scene=''>
-You may change the PDB parameter (which sets the PDB file loaded into the applet)
+== Structural highlights ==
-or the SCENE parameter (which sets the initial scene displayed when the page is loaded),
+<table><tr><td colspan='2'>[[3ti8]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Influenza_A_virus_(A/duck/Alberta/60/1976(H12N5)) Influenza A virus (A/duck/Alberta/60/1976(H12N5))]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3TI8 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=3TI8 FirstGlance]. <br>
-or leave the SCENE parameter empty for the default display.
+</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.601&#8491;</td></tr>
--->
+<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=CA:CALCIUM+ION'>CA</scene>, <scene name='pdbligand=LNV:5-(ACETYLAMINO)-2,6-ANHYDRO-4-CARBAMIMIDAMIDO-3,4,5-TRIDEOXY-7-O-METHYL-D-GLYCERO-D-GALACTO-NON-2-ENONIC+ACID'>LNV</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr>
-{{STRUCTURE_3ti8|  PDB=3ti8  |  SCENE=  }}
+<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=3ti8 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3ti8 OCA], [https://pdbe.org/3ti8 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=3ti8 RCSB], [https://www.ebi.ac.uk/pdbsum/3ti8 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=3ti8 ProSAT]</span></td></tr>
+</table>
+== Function ==
+[https://www.uniprot.org/uniprot/A1ILL9_I76A2 A1ILL9_I76A2]
+<div style="background-color:#fffaf0;">
+== Publication Abstract from PubMed ==
+The 2009 H1N1 influenza pandemic (pH1N1) led to record sales of neuraminidase (NA) inhibitors, which has contributed significantly to the recent increase in oseltamivir-resistant viruses. Therefore, development and careful evaluation of novel NA inhibitors is of great interest. Recently, a highly potent NA inhibitor, laninamivir, has been approved for use in Japan. Laninamivir is effective using a single inhaled dose via its octanoate prodrug (CS-8958) and has been demonstrated to be effective against oseltamivir-resistant NA in vitro. However, effectiveness of laninamivir octanoate prodrug against oseltamivir-resistant influenza infection in adults has not been demonstrated. NA is classified into 2 groups based upon phylogenetic analysis and it is becoming clear that each group has some distinct structural features. Recently, we found that pH1N1 N1 NA (p09N1) is an atypical group 1 NA with some group 2-like features in its active site (lack of a 150-cavity). Furthermore, it has been reported that certain oseltamivir-resistant substitutions in the NA active site are group 1 specific. In order to comprehensively evaluate the effectiveness of laninamivir, we utilized recombinant N5 (typical group 1), p09N1 (atypical group 1) and N2 from the 1957 pandemic H2N2 (p57N2) (typical group 2) to carry out in vitro inhibition assays. We found that laninamivir and its octanoate prodrug display group specific preferences to different influenza NAs and provide the structural basis of their specific action based upon their novel complex crystal structures. Our results indicate that laninamivir and zanamivir are more effective against group 1 NA with a 150-cavity than group 2 NA with no 150-cavity. Furthermore, we have found that the laninamivir octanoate prodrug has a unique binding mode in p09N1 that is different from that of group 2 p57N2, but with some similarities to NA-oseltamivir binding, which provides additional insight into group specific differences of oseltamivir binding and resistance.
-===Crystal structure of influenza A virus neuraminidase N5 complexed with laninamivir===
+Structural and functional analysis of laninamivir and its octanoate prodrug reveals group specific mechanisms for influenza na inhibition.,Vavricka CJ, Li Q, Wu Y, Qi J, Wang M, Liu Y, Gao F, Liu J, Feng E, He J, Wang J, Liu H, Jiang H, Gao GF PLoS Pathog. 2011 Oct;7(10):e1002249. Epub 2011 Oct 20. PMID:22028647<ref>PMID:22028647</ref>
+From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
+</div>
+<div class="pdbe-citations 3ti8" style="background-color:#fffaf0;"></div>
-<!--
+==See Also==
-The line below this paragraph, {{ABSTRACT_PUBMED_22028647}}, adds the Publication Abstract to the page
+*[[Neuraminidase 3D structures|Neuraminidase 3D structures]]
-(as it appears on PubMed at http://www.pubmed.gov), where 22028647 is the PubMed ID number.
+== References ==
--->
+<references/>
-{{ABSTRACT_PUBMED_22028647}}
+__TOC__
+</StructureSection>
-==About this Structure==
+[[Category: Large Structures]]
-[[3ti8]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Influenza_a_virus Influenza a virus]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3TI8 OCA].
+[[Category: Feng E]]
+[[Category: Gao F]]
-==Reference==
+[[Category: Gao GF]]
-<ref group="xtra">PMID:022028647</ref><references group="xtra"/>
+[[Category: He J]]
-[[Category: Influenza a virus]]
+[[Category: Jiang H]]
-[[Category: Feng, E.]]
+[[Category: Li Q]]
-[[Category: Gao, F.]]
+[[Category: Liu H]]
-[[Category: Gao, G F.]]
+[[Category: Liu J]]
-[[Category: He, J.]]
+[[Category: Liu Y]]
-[[Category: Jiang, H.]]
+[[Category: Qi J]]
-[[Category: Li, Q.]]
+[[Category: Vavricka CJ]]
-[[Category: Liu, H.]]
+[[Category: Wang J]]
-[[Category: Liu, J.]]
+[[Category: Wang M]]
-[[Category: Liu, Y.]]
+[[Category: Wu Y]]
-[[Category: Qi, J.]]
-[[Category: Vavricka, C J.]]
-[[Category: Wang, J.]]
-[[Category: Wang, M.]]
-[[Category: Wu, Y.]]
-[[Category: 6-bladed beta-propeller]]
-[[Category: Antiviral]]
-[[Category: Calcium binding]]
-[[Category: Glycosylation]]
-[[Category: Hydrolase-hydrolase inhibitor complex]]